Float Short %

14.93

Margin Of Safety %

-15

Put/Call OI Ratio

0.21

EPS Next Q Diff

EPS Last/This Y

4.28

EPS This/Next Y

-2

Price

5.88

Target Price

13.5

Analyst Recom

2.33

Performance Q

-39.19

Relative Volume

0.74

Beta

2.08

Ticker: EBS

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	EBS	4.58	0.37	0.57	8136
2025-04-15	EBS	4.64	0.37	1.32	8380
2025-04-16	EBS	4.63	0.39	0.00	8661
2025-04-17	EBS	4.62	0.38	0.10	8728
2025-04-18	EBS	4.62	0.38	0.10	8728
2025-04-21	EBS	4.55	0.30	0.11	7651
2025-04-22	EBS	4.72	0.29	0.04	8041
2025-04-23	EBS	4.99	0.29	0.01	8205
2025-04-24	EBS	5.36	0.27	0.70	8754
2025-04-25	EBS	5.49	0.28199084985443	0.24344176285414	9247
2025-04-28	EBS	5.45	0.29694739711093	0.44422310756972	9517
2025-04-29	EBS	5.45	0.31	0.00	10018
2025-04-30	EBS	5.36	0.22	0.24	13403
2025-05-01	EBS	4.91	0.23	0.02	13622
2025-05-02	EBS	5.13	0.22	0.06	13731
2025-05-05	EBS	4.95	0.20	0.21	13954
2025-05-06	EBS	4.78	0.20	0.78	14012
2025-05-07	EBS	4.74	0.21	0.06	14293
2025-05-08	EBS	6.36	0.21	0.31	14592
2025-05-09	EBS	5.65	0.21	0.43	15112
2025-05-12	EBS	5.84	0.22	0.02	15160
2025-05-13	EBS	5.89	0.21	0.07	15725
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	EBS	4.58	93.2	229.8	2.07
2025-04-15	EBS	4.63	93.2	228.2	2.07
2025-04-16	EBS	4.63	93.2	227.2	2.07
2025-04-17	EBS	4.62	93.2	227.8	2.07
2025-04-18	EBS	4.62	93.2	227.9	2.07
2025-04-21	EBS	4.55	93.2	227.1	2.07
2025-04-22	EBS	4.72	93.2	229.6	2.07
2025-04-23	EBS	4.98	93.2	230.5	2.07
2025-04-24	EBS	5.35	93.2	231.5	2.07
2025-04-25	EBS	5.49	93.2	228.9	2.07
2025-04-28	EBS	5.45	93.2	227.4	2.07
2025-04-29	EBS	5.45	93.2	227.9	2.07
2025-04-30	EBS	5.34	93.2	226.8	2.07
2025-05-01	EBS	4.92	93.2	-	2.07
2025-05-02	EBS	5.14	93.2	-	0.68
2025-05-05	EBS	4.95	18.6	-	0.68
2025-05-06	EBS	4.78	18.6	-	0.68
2025-05-07	EBS	4.74	18.6	-	0.68
2025-05-08	EBS	6.36	18.6	-	0.68
2025-05-09	EBS	5.65	18.6	-	0.68
2025-05-12	EBS	5.84	18.6	-	0.68
2025-05-13	EBS	5.88	128.9	-	0.68
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	EBS	-4.00	9.22	17.15
2025-04-15	EBS	-4.00	9.22	17.15
2025-04-16	EBS	-4.00	9.22	17.15
2025-04-17	EBS	-4.00	9.22	17.15
2025-04-18	EBS	-4.00	9.22	17.15
2025-04-21	EBS	-4.00	11.98	17.15
2025-04-22	EBS	-4.00	11.98	17.15
2025-04-23	EBS	-4.00	11.98	17.15
2025-04-24	EBS	-4.00	11.98	17.15
2025-04-25	EBS	-4.00	11.98	17.15
2025-04-28	EBS	-4.00	11.98	17.25
2025-04-29	EBS	-4.00	11.98	17.25
2025-04-30	EBS	-4.00	11.98	17.25
2025-05-01	EBS	-4.00	11.98	17.25
2025-05-02	EBS	-4.00	11.98	17.25
2025-05-05	EBS	-4.00	8.97	17.25
2025-05-06	EBS	-4.00	8.97	17.25
2025-05-07	EBS	-4.00	8.97	17.25
2025-05-08	EBS	-4.00	8.97	17.25
2025-05-09	EBS	-4.00	8.97	17.25
2025-05-12	EBS	-3.49	10.21	14.93
2025-05-13	EBS	-3.49	10.21	14.93
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.67

Avg. EPS Est. Next Quarter

-0.76

Insider Transactions

-3.49

Institutional Transactions

10.21

Beta

2.08

Average Sales Estimate Current Quarter

205

Average Sales Estimate Next Quarter

178

Fair Value

4.99

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

95.7

Max Drawdown 5-Year %

-98.9

Target Price

13.5

P/E

Forward P/E

PEG

P/S

0.33

P/B

0.58

P/Free Cash Flow

3.38

EPS

-2.71

Average EPS Est. Cur. Y

0.68

EPS Next Y. (Est.)

-1.32

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-13.63

Relative Volume

0.74

Return on Equity vs Sector %

-63.2

Return on Equity vs Industry %

-47.1

EPS 1 7Days Diff

-1.4

EPS 1 30Days Diff

-1.39

EBIT Estimation

Emergent BioSolutions Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 900

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

stock quote shares EBS – Emergent BioSolutions Inc. Stock Price stock today

news today EBS – Emergent BioSolutions Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch EBS – Emergent BioSolutions Inc. yahoo finance google finance

stock history EBS – Emergent BioSolutions Inc. invest stock market

stock prices EBS premarket after hours

ticker EBS fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: EBS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y